Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGON-1: EDP-305 in NASH
NCT03421431Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of EDP-305 in Nonalcoholic steatohepatitis (NASH), sponsored by Enanta Pharmaceuticals. Started Apr 2018; status: completed.
02
Drugs
EDP-305
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03421431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03421431.